Life sciences and biotech £86bn boost to science and tech in the UK to turbocharge economy £86bn to fund everything from new drug treatments and longer-lasting batteries to new AI breakthroughs to generate billions for the UK economy and drive our Plan for Change Latest Content Elsevier launches an AI tool to support faster and more reliable access to regulatory insights for drug development Qureight’s AI 3D imaging platform to support research on Idiopathic Pulmonary Fibrosis (IPF) Tackling real-world life science challenges with quantum computing New technologies Solution Accelerators for biotech research Merz consolidates its R&D with a Life Sciences platform White papers Centralising analytical data from mass spectrometry in drug discovery and development Discover how experts from Zoetis, Bayer, LifeMine Therapeutics, Iterion, Targenomix, and the Pistoia Alliance are solving key data challenges for mass spectrometry applications. Standardization of Analytical Data: Best Practices Standardization is critical to extracting the full potential of data. This White Paper offers a comprehensive guide to overcoming challenges and driving progress in analytical chemistry and beyond. Advancing the use of emerging computing infrastructure in Life Sciences RCH Solutions supports the adoption of novel computing technologies such as cloud, quantum, AI and edge computing paradigms through a co Webcasts On Demand Webinar: Consolidating computing resources can democratise research infrastructure More content Pistoia Alliance sets out its strategy to accelerate sustainability and the adoption of AI Which computing innovators made this year's Photonics100? Case study: Via Nova Therapeutics uses CDD Vault to support global collaboration Advancing bioscience research with machine learning Understanding infection with machine learning 2023 State of Tech in Biopharma report reveals tech strategies in era of data and AI Ganymede Bio and Kytopen to bring cloud-native structured data to gene-modified cell therapy Collaboration aims to facilitate regenerative cell therapy product development Uncovering the mechanisms underlying lack of response to immunotherapy Boosting biotech valuations with cost-efficient addition of key in silico evidence UK government invests £5.5 million in life sciences Acquistion expands Optibrium's 3D drug design and visualisation software Pagination Previous page ‹ Previous Page 11 Next page Next ›
